The SARS-CoV-2 pandemic revealed that existing U.S. manufacturing frameworks characterized by few facilities and lengthy and complex supply chains are fragile and strained from elevated business risks and shortages.
An industry study by MxD and IAAE between February and June 2021 funded by the FDA Office of Counterterrorism and Emerging Threats.
The FDA defined advanced manufacturing as “a collective term for new medical product manufacturing technologies that can improve drug quality, address shortages of medicines, and speed time-to-market.” The FDA also emphasizes the public health advantages of adopting continuous and additive manufacturing methods.
Results from this FDA-funded research increase the understanding of factors that impact a manufacturer’s decision to invest in and adopt digital technologies. Analysis of interview data from manufacturer representatives revealed areas for improvement and opportunities for enhancing manufacturing resilience.